Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Colorcon
AstraZeneca
Medtronic
Merck

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,465,462

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,465,462
Title:Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
Abstract:A multiparticulate controlled release selective serotonin reuptate inhibitor (SSRI) formulation for oral administration is provided. The formulation includes particles of an SSRI or a pharmaceutically acceptable salt thereof, which are coated with a rate-controlling polymer that allows controlled release of the SSRI over a period of not less than about 12 hours after oral administration. The rate controlling polymer includes a film-forming water-insoluble polymer, or a mixture of a film-forming water-insoluble polymer and a film-forming water-soluble polymer.
Inventor(s): Jeary; Theresa Ann (Roscommon, IE), Morrissey; Catherine Ann (County Westmeath, IE), Stark; Paul (County Westmeath, IE)
Assignee: Elan Pharma International Limited (Monksland Athlone County Westmeath, IL)
Application Number:09/744,169
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,465,462
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Device; Use;

Drugs Protected by US Patent 7,465,462

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Jazz Pharms LUVOX CR fluvoxamine maleate CAPSULE, EXTENDED RELEASE;ORAL 022033-001 Feb 28, 2008 DISCN Yes No   Start Trial   Start Trial Y TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI   Start Trial
Jazz Pharms LUVOX CR fluvoxamine maleate CAPSULE, EXTENDED RELEASE;ORAL 022033-002 Feb 28, 2008 DISCN Yes No   Start Trial   Start Trial Y TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,465,462

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Ireland990406May 20, 1999
PCT Information
PCT FiledMay 10, 2000PCT Application Number:PCT/IE00/00060
PCT Publication Date:November 30, 2000PCT Publication Number: WO00/71099

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
McKinsey
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.